Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024

“Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024” Report Highlight:

• Global Peptide Therapeutics Market Opportunity: More Than US$ 50 Billion
• Cost Analysis & Market Insight into its Application
• Dosage & Sales Analysis of Key Drugs
• Global Peptide Drug Clinical Pipeline: 612 Drugs
• Peptide Drug Application  by Indication
• Global Peptide Pipeline by Indication, Company & Phase
• Marketed Peptide Drugs: 101 Drugs
• Clinical Trials Insight by Peptide Classification

 

Peptide based therapeutics are currently experiencing a renaissance in the global market with collective sales of more than US$ 20 Billion in 2017. Therapeutics such as Lantus, from Sanofi has recently managed to become a blockbuster peptide therapeutic with record sales of over US$ 8 Billion in 2017. Overall, the global peptide therapeutics market is expected to surpass US$ 50 Billion by 2024 from less than US$ 30 Billion in 2018. The overall market growth will be driven by the increasing research and development expenditure by pharmaceutical organizations along with rapid entry of multiple peptide based drug in the market.

 

Download Peptide Market Clinical Trial Pipeline Reporty Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Peptide-Therapeutics-Market-Dosage-Price-%26-Clinical-Trials-Insight-2024

 

Report TOC

1. Emergence of Peptide Therapeutics: New Growth Frontier For Pharmaceutical Industry

1.1 Peptides as Drug Candidates

1.2 Why Need for Peptide Therapeutics?

 

2. Cusp of Small Molecules & Proteins

2.1 Peptides v/s Small Molecules

2.2 Peptides v/s Protein Biologics

 

3. Fundamentals of Peptide Therapeutics

3.1 Rational Design for Novel Peptides

3.2 Aspects of Regulatory Approvals

 

4. Peptide Therapeutics – Cost Analysis & Market Insight into its Application

4.1 Application of Peptides in Imaging

4.2 Application of Peptides in Diseases

 

5. Peptide Therapeutics For Treatment of Metabolic Disorder

5.1 Prologue to Metabolic Disorders

5.2 Approved Peptide Drugs for Metabolic Disorders – Cost & Dosage Analysis

5.3 Market of Metabolic Peptides

 

6. Peptide Therapeutics in Cancer – Drug Price & Therapy Cost Analysis

6.1 Prologue to Cancer

6.2 Dose & Price Analysis of Peptide Cancer Therapeutics

6.2.1 Abralix

6.2.2 Degarelix

6.2.3 Octreotide

6.2.4 Leuprolide

6.2.5 Sipuleucel-T ( Provenge)

6.2.6 Goserelin (Zoladex)

6.3 Cancer Peptide Therapeutics – Sales Analysis

 

7. Peptide Therapeutics For Treatment of Cardiovascular Disease

7.1 Prologue to Cardiovascular Diseases

7.2 Approved Peptide Drugs in Cardiovascular Diseases

7.3 Cardiac Peptide Therapeutics – Sales Analysis

 

8. Peptide Therapeutics For Treatment of HIV Infections

8.1 Prologue to Infections

8.2 Approved Peptide Therapeutics in Infections

8.3 Anti-Infectious Peptides – Sales Analysis

 

9. Peptide Therapeutics For Treatment of CNS Disorders

9.1 Prologue to CNS Disorders

9.2 Neuropeptides Drug Delivery to CNS

9.3 Future Market Potential

 

10. Global Peptide Therapeutics Market Current Scenario

10.1 Overview

10.2 Peptide Market by Application

 

11. Global Peptides Drug Clinical Pipeline Overview

11.1 Cyclic Peptides

11.2 Depsipeptides

11.3 Dipeptides

11.4 Glycopeptides

11.5 Lipopeptides

11.6 Natriuretic Peptides

11.7 Neuropeptides

11.8 Oligopeptides

11.9 Opioid Peptides

11.10 Peptides

11.11 Multiple Peptides

 

12. Global Peptide Market by Route of Administration

12.1 Current Trends in Route of Administration

12.2 Current Trends over the Peptide Products

 

13. Global Peptide Market by Region

13.1 North America

13.2 Europe

13.3 Asia

14. Global Peptide Drug Market Dynamics

14.1 Favorable Parameters

14.2 Challenges

 

15. Global Peptide Therapeutics Market Future Outlook

15.1 Future Trends in Peptide Therapeutics

15.2 Future Opportunities of Peptides Therapeutics

 

16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company

16.1 Preclinical till Preregistration

16.2 Marketed

 

17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company

17.1 Preclinical till Preregistration

17.2 Marketed

 

18. Dipeptides Clinical Trials Insight by Phase, Indication & Company

18.1 Preclinical till Preregistration

18.2 Marketed

 

19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company

19.1 Preclinical till Preregistration

19.2 Marketed

 

20. Lipopeptides Clinical Trials Insight by Phase, Indication & Company

20.1 Preclinical till Preregistration

 

21. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company

21.1 Preclinical till Preregistration

21.2 Marketed

 

22. Neuropeptides Clinical Trials Insight by Phase, Indication & Company

22.1 Preclinical till Preregistration

22.2 Marketed

 

23. Oligopeptides Clinical Trials Insight by Phase, Indication & Company

23.1 Preclinical till Preregistration

23.2 Marketed

 

24. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company

24.1 Preclinical till Preregistration

24.2 Marketed

 

25. Peptides Clinical Trials Insight by Phase, Indication & Company

25.1 Preclinical till Preregistration

25.2 Marketed

 

26. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company

26.1 Preclinical till Preregistration

26.2 Marketed

 

27. Competitive Landscape

27.1 Amgen

27.2 Amylin Pharmaceuticals

27.3 Apitope Technology

27.4 BioPartners

27.5 BiondVax Pharmaceuticals Ltd

27.6 Boehringer Ingelheim

27.7 Circassia

27.8 Corden Pharma (Peptisyntha)

27.9 Eli Lily

27.10 Galena Biopharmaceuticals

27.11 GlaxoSmithKline

27.12 Hyperion Therapeutics

27.13 ImmunoCellular Therapeutics

27.14 Ipsen

27.15 Lonza

27.16 Merck

27.17 NovoNordisk

27.18 Par Pharmaceuticals

27.19 PeptiDream

27.20 Roche

27.21 Sanofi

27.22 Tarix Pharmaceuticals